Anika Therapeutics
ANIKAnika Therapeutics is a global healthcare company specializing in early intervention orthopedic solutions and osteoarthritis (OA) pain management.
Earnings
Next report
Date not yet announcedFinancials
Q2 2026Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Anika Therapeutics is a global healthcare company specializing in early intervention orthopedic solutions and osteoarthritis (OA) pain management. The company leverages its proprietary hyaluronic acid (HA) technology platform to develop and manufacture minimally invasive products that restore active living. Its core value proposition lies in providing a full continuum of care from pain relief injections to regenerative scaffolds for joint and soft tissue repair.
A leading specialist in hyaluronic acid technology with a dominant market share in the U.S. viscosupplement market through strategic licensing partnerships.
Questions, answered.
- What is Anika Therapeutics's market cap?
- Anika Therapeutics (ANIK) has a market capitalization of $199.9M and trades on NASDAQ.
- What is Anika Therapeutics's revenue and profitability?
- Anika Therapeutics generated $120.7M in trailing twelve-month revenue with a net loss of $4.1M, representing a net margin of -3.4%, with free cash flow of $562.0K. These figures are based on the Q2 2026 filing.
- Who are Anika Therapeutics's competitors?
- Anika Therapeutics's key competitors include Bioventus Inc., Pacira BioSciences, Zimmer Biomet, Inc., and others. These companies compete in similar markets and product categories.
- Who does Anika Therapeutics partner with?
- Anika Therapeutics's notable partners include Johnson & Johnson MedTech, Phoenix Brio, Incorporated, Medacta Americas Manufacturing, Inc..
- Where is Anika Therapeutics headquartered?
- Anika Therapeutics is headquartered in United States of America and employs approximately 357 people. It has been publicly traded since 1993.
